Specialist asset manager Intermediate Capital Group (ICG) has made its Finnish debut with the acquisition of a life sciences facility in Vantaa.
Via its subsidiaries, ICG has purchased Thermo Fisher Scientific’s mission critical headquarter office and R&D facility. The S&P 100 company has a long net lease agreement for the property, which spans over 23,000 m2 of lettable area.
The property was built in 2002 to serve as Thermo Fisher Scientific’s Finnish headquarters and is situated close to the airport with good road and rail connections, providing what broker JLL calls 'the perfect place' to combine office, laboratory and warehouse functions.
Chad Brown, managing director, Intermediate Capital Group: 'ICG’s SLB fund is pleased to close the acquisition of this highly mission critical facility, in what is, our first investment in Finland.
'Finland and the Nordics are a key target market for our strategy and we are actively seeking additional mission critical real estate opportunities. ICG worked closely with JLL on this transaction and valued their support entering the Finnish market.'
Antti Pelli, senior director capital markets at JLL Finland said: 'We are pleased to have been able to successfully advise ICG in their inaugural transaction in the Finnish property market.
'The transaction demonstrates Finland’s continuing appeal to international investors and is a testament of JLL’s ability to assists its clients across sectors and geographies.'
JLL acted as ICG’s sole commercial advisor in the transaction. Krogerus acted as ICG’s legal advisor.
